Avoid common mistakes on your manuscript.
Past
Patients with pancreatic ductal adenocarcinoma (PDAC) with a Lewis antigen-negative phenotype secrete very little or no carbohydrate antigen (CA) 19-9. Therefore, PDAC patients with normal CA 19-9 levels can have early-stage cancer or advanced cancer without elevation of CA19-9 level; thus, estimating their malignant potential is difficult.
Future
The combined use of CA19-9 and DUPAN-2 may define a novel criterion of borderline resectability.
References
Shimizu Y, Sugiura T, Ashida R, et al. Prognostic role of preoperative duke pancreatic monoclonal antigen type 2 levels in patients with pancreatic cancer. Ann Surg Oncol. 2023;30:5792–800.
Sumiyoshi T, Uemura K, Shintakuya R, et al. Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15221-z.
Funding
Open Access funding provided by Hiroshima University. This study received no financial support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors declare no conflicts of interest associated with this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article refers to: Sumiyoshi T, Uemura K, Shintakuya R, et al. Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma. Ann Surg Oncol. (2024). https://doi.org/10.1245/s10434-024-15221-z.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sumiyoshi, T., Uemura, K. ASO Author Reflections: Accurate Evaluation of Malignant Potential in Pancreatic Ductal Adenocarcinoma Using DUPAN-2 Level. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15272-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1245/s10434-024-15272-2